Axsome Therapeutics, Inc. cotiza a 166.00 USD y tiene una capitalización bursátil de $8.7B. En los últimos 12 meses ha facturado $777M con un margen de flujo de caja libre del -14.7%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.99 | $-1.26 | $-0.56 |
| Estimado | $-0.54 | $-0.78 | $-0.86 | $-0.73 |
| Sorpresa | — | -26.9% | -46.5% | +23.3% |
| Métrica | AXSM | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 92.6% | 57.0% | +35.5% |
| Operating Margin | -26.1% | -38.6% | +12.5% |
| Net Margin | -28.7% | -33.6% | +4.9% |
| FCF Margin | -14.7% | -13.9% | -0.8% |
| ROE | -207.5% | -40.4% | -167.1% |
| ROA | -26.6% | -32.0% | +5.5% |
| Current Ratio | 1.55 | 2.84 | -1.29 |
| Debt / Equity | 1.33 | 0.28 | +1.05 |